U.S. women’s telehealth provider Wisp has entered a strategic partnership with Vesalius Longevity Labs to co-develop a new line of peptide therapeutics tailored to women’s biological needs, according to the companies.
Vesalius, known for its Peptual brand of peptides and bioregulators, will collaborate with Wisp to design therapies targeting stages such as fertility, menopause, and healthy aging. The companies said they also plan to explore artificial intelligence platforms for integration into patient care and personalized decision support.
The global peptide therapeutics market is estimated at about US$ 43.1 billion and is projected to reach US$ 106 billion by 2033, the companies note. They contend that most recent growth has centered on male-oriented applications, and that the joint effort could roughly double the addressable market by focusing on women.
The new peptide product portfolio is expected to launch in early 2026, leveraging Vesalius’ existing formulations, which include injectables, patches, nasal sprays, oral and topical versions sourced primarily in the U.S. Wisp’s move into longevity follows its recent rollout of two supplements—Wisp Thrive Creatine Tablets and Wisp Revive Collagen Tablets.
Wisp currently serves more than 1.5 million patients across the U.S., offering telehealth solutions spanning contraception, fertility, menopause and other women’s health needs. According to Vesalius, it operates a B2Doctor ecosystem to deliver its peptide portfolio from clinical development through commercialization.
